LEVETIRACETAM TEVA ® 250 MG

Israel - English - Ministry of Health

Buy It Now

Active ingredient:
LEVETIRACETAM 250 MG
Available from:
TEVA PHARMACEUTICAL INDUST.LTD
ATC code:
N03AX14
Pharmaceutical form:
TABLETS
Administration route:
PER OS
Manufactured by:
TEVA PHARMACEUTICAL INDUSTRIES LTD
Therapeutic group:
LEVETIRACETAM
Therapeutic indications:
- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Authorization number:
141433195800
Authorization date:
2009-09-01

Documents in other languages

Patient Information leaflet Patient Information leaflet - Arabic

21-01-2021

Patient Information leaflet Patient Information leaflet - Hebrew

21-01-2021

Similar products

Search alerts related to this product

View documents history

Share this information